Skip to content

Care Assessment Platform Research Project

The use of ambulatory monitoring devices to develop a software platform that can support the delivery of community based care for people with or at risk of developing cardiovascular or chronic obstructive pulmonary disease.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12606000295549
Enrollment
40
Registered
2006-07-11
Start date
2006-09-22
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The project will involve monitoring a patient’s activity levels and vital signs to determine their response to targeted exercise therapy, education programs and changes in medications. This data will be measured using an externally worn monitoring device. Changes in medications and related health observations will be captured using a form. Patient’s perceived Quality-of-Life, self assessed activity levels and trial feedback (satisfaction, inconvenience etc) will also be captured by questionnaire. It is also desired to link hospital readmission and length of stay measures with the involvement of participants in the study.

Interventions

The study involves continuous monitoring of movement and cardiac signals in three patient groups: 1. Management and tertiary prevention: patients with developed cardiovascular diseases and/or COPD that are assessed and managed by Home Based Acute Care services. 2. Secondary prevention: early detection and early management of disease markers. These patients live at home at attend rehab clinics twice weekly for exercise and other intervention therapy. 3. Primary prevention: preventing and reducin

The study involves continuous monitoring of movement and cardiac signals in three patient groups: 1. Management and tertiary prevention: patients with developed cardiovascular diseases and/or COPD that are assessed and managed by Home Based Acute Care services. 2. Secondary prevention: early detection and early management of disease markers. These patients live at home at attend rehab clinics twice weekly for exercise and other intervention therapy. 3. Primary prevention: preventing and reducing risk factors. This cohort will be healthy community participants, serving as a control group. Participants will be monitored 24hours/day for 10-15 weeks, using a device worn on the hip, containing accelerometers and a single channel ECG module, connected to the chest via leads & adhesive electrode pads. The following observations will be made at the completion of the study: • Degree of adjustment to patient therapy as a result of frequent / continuous assessment of mobility; • Ability to identify patients that respond well to certain exercise /education from those that don’t respond; • Patient activity levels through the week between visits to rehabilitation clinics; • Extent of changes in activity levels as a direct consequence of modifying medications; • Contribution of ECG monitoring to the management and care of participants; • Duplication levels in patient assessment; • Ability to use monitoring for benchmarking rehabilitation services; • Patient and clinician perceived continuum of care and communication of health information; • Activity levels of study participants over previous levels; • Hospital admission and length of stay data for participants in the study.

Sponsors

CSIRO (E-Health Research Centre)
Lead SponsorGovernment body

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Accessing clinical services through the North Lakes Models of Care, displaying symptoms or risk factors of cardiovascular diseases or COPD.• Community volunteers consenting to act as a healthy control group.• Participants who are assessed as being competent to consent to their participation in the study, or who have a competent caregiver who can consent on their behalf.

Exclusion criteria

Patients with permanent or temporary cardiac pacemakers and other implantable devices.• Patients using electrical infusion devices. • People fitted with other patient-borne electronic devices except external hearing aids.• People assessed as having an “at risk” skin assessment.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026